Global sales of total semiconductor manufacturing equipment by original equipment manufacturers (OEMs) are forecast to reach ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high ...

At the 2025 IEEE International Electron Devices Meeting (IEDM), research centre Imec is presenting breakthrough performance of p-type FETs with monolayer WSe 2 channels, and improved fab-compatible ...

Every nation and organization has the right to determine how its digital resources are governed, protected and shared.

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...

What happens when inclusion is treated not as a separate initiative, but as a creative advantage, an audience strategy, and a ...

The participants First Spark is a deep tech venture capital fund investing in breakthrough technologies. Olcott said that he ...

Investing.com -- Senti Biosciences (NASDAQ:SNTI) stock surged 29% after the company reported positive clinical trial results for its cancer therapy SENTI-202 and received FDA Regenerative Medicine ...

Applied Materials' AI-fueled gains lift shares 56% this year, but export limits, rivals and valuation cloud the near-term outlook.

Senti Biosciences (NASDAQ:SNTI) soared 29% on Tuesday after unveiling encouraging clinical data from its SENTI-202 cancer ...

For Jews accustomed to celebrating Hanukkah as a minority, this difference is striking. In much of the Diaspora, Hanukkah has ...